We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genedata Extends Lead Discovery Collaboration with Novartis
News

Genedata Extends Lead Discovery Collaboration with Novartis

Genedata Extends Lead Discovery Collaboration with Novartis
News

Genedata Extends Lead Discovery Collaboration with Novartis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genedata Extends Lead Discovery Collaboration with Novartis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genedata has announced that it has scaled-up its collaboration in high throughput screening analysis with Novartis Institutes for Biomedical Research (NIBR).

Genedata’s agreement with Novartis includes round the clock support for the Genedata Screener® platform in Cambridge (MA), USA and Basel, Switzerland.

"Novartis sought an innovative partner to deliver advanced analysis and visualization tools for HTS analysis," explained Dr. Stephan Heyse, Head of Screener.

The collaboration with Genedata was initiated with Novartis Discovery Technologies, a core component of the NIBR.

Novartis cultivates close development partnerships through its Discovery Technologies program.

Successful collaborations are scaled-up and applied at the Company’s research sites globally.

Scientists at Novartis use Screener to pinpoint quality issues in screening data as part of a highly automated analysis workflow. The software is designed to validate entire screens in a standardized fashion.

Dr. Heyse added, "This saves time and minimizes the risk that lead compounds fail at later phases of drug development."

Advertisement